Melanoma skin cancer tumours grow larger and are more likely to metastasise due to interactions between a pair of molecules, according to experiments in mice and human cells.

The results may restore the potential for a type of cancer therapy previously abandoned in clinical trials.

The results also implicate one molecule already connected to obesity and dementia as a potential cause of metastasis, or spread of cancer cells to other areas of the body.

Melanoma accounts for about 1 percent of skin cancers, but causes a large majority of skin cancer deaths, according to the American Cancer Society.

Few treatments exist to prevent melanoma from metastasising.

A research team led by Associate Professor Beate Heissig at the University of Tokyo Institute of Medical Science has studied tissue type plasminogen activator (tPA) for over a decade.

tPA is a protease, a small molecule that can cut proteins.

tPA bonds to a larger protein that sits within the membrane barrier of animal cells, called low-density lipoprotein receptor-related protein 1 (LRP1).

Heissig's research team proposes blocking the metastasis-promoting action of tPA by preventing it from connecting to LRP1.

Mice without LRP1 had smaller tumours, even when researchers provided extra tPA.

Other studies have linked LRP1 to chronic diseases including diabetes, obesity, and Alzheimer's disease.

"It's surprising that LRP1 is also regulating cancer growth and spread. It's normally a receptor for fat molecules," said Heissig.

In 2016, Heissig's research group discovered that mice given extra tPA had greater numbers of a specific type of cell.

This same cell type usually increases within the melanoma tumours and can enhance tumour growth.

Based on that potential connection, the current project was designed to investigate what role tPA might play in skin cancer.

When cancer cells metastasise, they use proteases to cut through the matrix of protein chains that holds healthy cells in place.

When cancer cells arrive in a new part of the body and begin to form new tumours, they corrupt nearby cells to build a niche, or supportive home for themselves.

Clinical researchers have attempted to prevent metastasis by stopping proteases.

However, completely blocking all proteases causes unintended side effects.

No protease-based cancer therapy has succeeded in clinical trials.

"Our vision is a cancer therapy that specifically prevents the interaction of LRP1 and tPA so that only the metastasis effect of the protease is stopped. Better understanding of the specific interactions of LRP1 and tPA will hopefully lead to protease cancer treatments that maintain the normal, healthy protease actions of tPA," said Yousef Salama, first author of the research paper and postdoctoral researcher in Heissig's lab.

Salama also suggests that tPA may be linked to cancer immunotherapy, the life-saving treatment awarded the 2018 Nobel Prize in Physiology or Medicine.

"The scientific community knows that tPA can interfere with the cell signals being studied for cancer immunotherapy. Blocking tPA could enhance the immune system's action and potentially boost the effectiveness of cancer immunotherapy treatments," said Salama.

Source: IRB Barcelona